Brief: Astrazeneca Pharma India Receives Permission To Import Datopotamab Deruxtecan Powder To India
17/12/2025 15:35
Dec 17 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS: RECEIVES PERMISSION TO IMPORT DATOPOTAMAB DERUXTECAN POWDER TO INDIA Source text: ID:nBSE6gMqtK Further company coverage: ASTR.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astrazeneca Pharma India
See all newsBrief: Astrazeneca Pharma Gets Permission To Import For Sale Of Trastuzumab Deruxtecan
India's Astrazeneca Pharma logs worst slide in two months on quarterly profit drop
Brief: Astrazeneca Pharma India March-Quarter PAT 448.8 Million Rupees
Brief: Astrazeneca Pharma India Recommends Dividend Of 36 Rupees Per Equity Share For Fy2025-26
Brief: Astrazeneca Pharma India Receives Permission To Import Durvalumab (Imfinzi) For Additional Indication